Clinical Trial Update: Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). [Phase 2]

View source ↗

Summary

A phase 2 trial of Aumolertinib for EGFR-mutant resected non-small cell lung cancer (AERESA) was withdrawn, with no results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer | Phase 2 | Status: WITHDRAWN